Bemiparin, an effective and safe low molecular weight heparin: a review. (Q38198458)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Bemiparin, an effective and safe low molecular weight heparin: a review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Francesca Cortese

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Filomena Corbo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Pietro Scicchitano

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Noel Ernesto Corrales

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Abdul Kareem Al-Momen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Antonio Silva

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Annapaola Zito

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mariangela Pinto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Michele Gesualdo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

19 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

published in

Vascular Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

32-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657810%20AND%20SRC:MED&resulttype=core&format=json

Bemiparin: pharmacological profile

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Bemiparin improves the total antioxidant status in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Effects of bemiparin, dalteparin, and unfractionated heparin on platelet interaction with human subendothelium under flow conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Effects of bemiparin on airway responses to antigen in sensitized Brown-Norway rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Clinical Experience with Bemiparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Fixed-dose low-molecular-weight heparin, bemiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

New frontiers with bemiparin: use in special populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Use of Low-Molecular-Weight Heparins and New Anticoagulants in Elderly Patients with Renal Impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Venous thromboembolic disease in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

[Triple-blind clinical trial with placebo control to evaluate the efficacy of a heparin of low molecular weight (bemiparin) for treating slow-responding ulcers in diabetic foot in primary care]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

7 January 2021

Bemiparin in oncology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

American College of Chest Physicians evidence-based guidelines for venous thromboembolic prophylaxis: the guideline wars are over

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001

Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.001